Type IV collagen levels are elevated in the serum of patients with peritoneal dissemination of gastric cancer

Kinoshita,Jun; Fushida,Sachio; Harada,Shinichi; Makino,Isamu; Nakamura,Keishi; Oyama,Katsunobu; Fujita,Hideto; Ninomiya,Itasu; Fujimura,Takashi; Kayahara,Masato; Ohta,Tetsuo

doi:10.3892/ol.2010.181

Type IV collagen levels are elevated in the serum of patients with peritoneal dissemination of gastric cancer

Authors:
- Jun Kinoshita
- Sachio Fushida
- Shinichi Harada
- Isamu Makino
- Keishi Nakamura
- Katsunobu Oyama
- Hideto Fujita
- Itasu Ninomiya
- Takashi Fujimura
- Masato Kayahara
- Tetsuo Ohta
View Affiliations

Affiliations: Department of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Ishikawa 920-8641, Japan, Center for Biomedical Research and Education, School of Medicine, Kanazawa University, Ishikawa, Japan
Published online on: September 23, 2010 https://doi.org/10.3892/ol.2010.181
Pages: 989-994

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Type III procollagen (amino-terminal propeptide of procollagen type III) and type IV collagen are considered to be reliable serum markers for monitoring the progression of liver fibrosis. The peritoneal dissemination of gastric cancer is also characterised by abundant collagen deposition in the peritoneum. The present study was performed to investigate the potential of serum type III procollagen and IV collagen as biomarkers for peritoneal dissemination in gastric cancer. The study population consisted of 117 patients with gastric cancer: 32 patients had peritoneal dissemination which was pathologically diagnosed by laparotomy or laparoscopic examination, while 85 patients (45/40, early/advanced gastric cancer) had no peritoneal dissemination. We measured the serum levels of type III procollagen and type IV collagen in comparison to the commonly accepted tumor markers carcinoembryonic (CEA), carbohydrate antigen (CA)19-9 and CA125. The median type III procollagen levels showed no significant differences between the two groups, whereas the median type IV collagen levels were significantly (201 ng/ml) higher in patients with than in those without peritoneal dissemination (early/advanced gastric cancer, 124/136 ng/ml) (P<0.05). In receiver operating characteristic (ROC) curve analysis, type IV collagen had the largest area under the curve (0.83), followed by CA125 (0.72), CA19-9 (0.64), CEA (0.59) and type III procollagen (0.48). Type IV collagen was an independent marker (P<0.0001, odds ratio 15.7) for predicting peritoneal dissemination along with CA125 (P=0.0086, odds ratio 9.4) based on multivariate logistic regression. In conclusion, serum type IV collagen levels may be significant in the early detection and management of patients with peritoneal dissemination of gastric cancer.

View Figures

View References

1	Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
2	Yamazaki H, Oshima A, Murakami R, Endoh S and Ubukata T: A long-term follow-up study of patients with gastric cancer detected by mass screening. Cancer. 63:613–617. 1989. View Article : Google Scholar : PubMed/NCBI
3	Ikeguchi M, Yamamoto O and Kaibara N: Management protocol for scirrhous gastric cancer. In Vivo. 18:577–580. 2004.PubMed/NCBI
4	Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY and Shen KH: Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology. 49:874–877. 2002.PubMed/NCBI
5	Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.PubMed/NCBI
6	Glehen O, Mohamed F and Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 5:219–228. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H and Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
8	Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M and Ohta T: Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 19:1305–1310. 2008.
9	Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 12:3402–3407. 2006. View Article : Google Scholar : PubMed/NCBI
10	Burke EC, Karpeh MS, Conlon KC and Brennan MF: Laparoscopy in the management of gastric adenocarcinoma. Ann Surg. 225:262–267. 1997. View Article : Google Scholar : PubMed/NCBI
11	Gretschel S, Siegel R, Estévez-Schwarz L, Hünerbein M, Schneider U and Schlag PM: Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg. 93:1530–1535. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sendler A, Dittler HJ, Feussner H, Nekarda H, Bollschweiler E, Fink U, Helmberger H, Höfler H and Siewert JR: Preoperative staging of gastric cancer as precondition for multimodal treatment. World J Surg. 19:501–508. 1995. View Article : Google Scholar : PubMed/NCBI
13	Davies J, Chalmers AG, Sue-Ling HM, May J, Miller GV, Martin IG and Johnston D: Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut. 41:314–319. 1997. View Article : Google Scholar : PubMed/NCBI
14	Düx M, Richter GM, Hansmann J, Kuntz C and Kauffmann GW: Helical hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr. 23:913–922. 1999.PubMed/NCBI
15	Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y and Furukawa H: The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho. 33:1817–1821. 2006.PubMed/NCBI
16	Nakata B, Hirakawa YS, Chung K, Kato Y, Yamashita Y, Maeda K and Onoda N: Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 83:2488–2492. 1998. View Article : Google Scholar : PubMed/NCBI
17	Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as ‘soil’ for peritoneal dissemination. Cancer. 77:1668–1675. 1996.PubMed/NCBI
18	Gabrielli GB and Corrocher R: Hepatic fibrosis and its serum markers. Dig Dis. 9:303–316. 1991. View Article : Google Scholar : PubMed/NCBI
19	Yamada S, Suou T, Kawasaki H and Yoshikawa N: Clinical significance of serum 7S collagen in various liver diseases. Clin Biochem. 25:467–470. 1992. View Article : Google Scholar : PubMed/NCBI
20	Jeffers LJ, Coelho-Little ME, Cheinquer H, Vargas C, Civantos F and Alvarez L: Procollagen-III peptide and chronic viral C hepatitis. Am J Gastroenterol. 90:1437–1440. 1995.PubMed/NCBI
21	Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study. 12th edition. Kanehara Shuppan; Tokyo: 1993
22	Kasuga I, Yonemaru M, Kiyokawa H, Ichinose Y and Toyama K: Clinical evaluation of serum type IV collagen 7S in idiopathic pulmonary fibrosis. Respirology. 1:277–281. 1996. View Article : Google Scholar : PubMed/NCBI
23	Sato Y, Kataoka K, Matsumori A, Sasayama S, Yamada T and Ito H: Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart. 78:505–508. 1997. View Article : Google Scholar
24	Guseva NG, Anikina NV, Myllylä R, Risteli L, Risteli J and Chochlova JV: Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis. Ann Rheum Dis. 50:481–486. 1991. View Article : Google Scholar : PubMed/NCBI
25	Xu X, Wu Z, Zhou Q, Zhang Y and Wu D: The role of determining the levels of serum collagen type IV in diagnosing early diabetic nephropathy. Ren Fail. 24:747–753. 2002. View Article : Google Scholar : PubMed/NCBI
26	Katayama M, Hino F, Kamihagi K, Sekiguchi K, Titani K and Kato I: Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem. 37:466–471. 1991.
27	Basso D, Belluco C, Mazza S, Greco E, Della Rocca F, Pauletto P, Nitti D, Lise M and Plebani M: Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen: clinical implications for prognosis. Clin Chim Acta. 312:135–142. 2001. View Article : Google Scholar
28	Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU and Pusztai L: Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer. 99:68–71. 2008. View Article : Google Scholar : PubMed/NCBI
29	Akazawa S, Fujiki T, Kanda Y, Kumai R and Yoshida S: Diagnostic values of serum type III procollagen N-terminal peptide in type IV gastric cancer. Gan To Kagaku Ryoho. 12:861–866. 1985.PubMed/NCBI
30	Korenaga D, Orita H, Maekawa S, Itasaka H, Ikeda T and Sugimachi K: Peritoneal collagen type IV concentration in adenocarcinoma of the gastrointestinal tract and its relationship to histological differentiation, metastasis, and survival. Surg Today. 28:780–786. 1998. View Article : Google Scholar
31	Baker SG: The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst. 95:511–515. 2003. View Article : Google Scholar
32	Martinez-Hernandez A and Amenta PS: The basement membrane in pathology. Lab Invest. 48:656–677. 1983.
33	Liotta LA: Tumor invasion and metastases – role of the extracellular matrix. Cancer Res. 46:1–7. 1986.
34	Meyer T and Hart IR: Mechanisms of tumor metastasis. Eur J Cancer. 34:214–221. 1998. View Article : Google Scholar
35	Conway JG, Trexler SJ, Wakefield JA, Marron BE, Emerson DL and Bickett DM: Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis. 14:115–124. 1996. View Article : Google Scholar : PubMed/NCBI
36	Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 149:273–282. 1996.PubMed/NCBI
37	Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, Haraguchi M, Ueo H and Akiyoshi T: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer. 74:316–321. 1997. View Article : Google Scholar : PubMed/NCBI
38	De Mingo M, Morán A, Sánchez-Pernaute A, Iniesta P, Díez-Valladares L, Pérez-Aguirre E, de Juan C, García-Aranda C, Díaz-López A, García-Botella A, Martín-Antona E, Benito M, Torres A and Balibrea JL: Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology. 54:315–319. 2007.PubMed/NCBI
39	Duffy MJ, Maguire TM, Hill A, McDermott E and O’Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:252–257. 2000. View Article : Google Scholar : PubMed/NCBI
40	Kenny HA, Kaur S, Coussens LM and Lengyel E: The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 118:1367–1379. 2008. View Article : Google Scholar : PubMed/NCBI
41	Sun XM, Dong WG, Yu BP, Luo HS and Yu JP: Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol. 9:2592–2595. 2003.PubMed/NCBI
42	Minamoto T, Ooi A, Okada Y, Mai M, Nagai Y and Nakanishi I: Desmoplastic reaction of gastric carcinoma: a light-and electron-microscopic immunohistochemical analysis using collagen type-specific antibodies. Hum Pathol. 19:815–821. 1998. View Article : Google Scholar